Nuvation Bio Reports Long-Term Efficacy Data for IBTROZI®
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NUVB?
Source: PRnewswire
- Efficacy Highlights: At AACR 2026, IBTROZI® (taletrectinib) demonstrated an 89.8% objective response rate in TKI-naïve patients, with a median duration of response of 49.7 months, indicating significant efficacy in treating ROS1-positive non-small cell lung cancer.
- Survival Extension: The long-term data analysis revealed a median progression-free survival of 46.1 months for TKI-naïve patients, reflecting IBTROZI's potential to extend patient survival and possibly redefine treatment standards for this disease.
- Favorable Safety Profile: Safety analysis of IBTROZI showed a low treatment discontinuation rate of only 8.5% due to adverse events, with no new safety signals identified, indicating its feasibility for long-term use.
- CNS Activity: IBTROZI exhibited a 76.5% intracranial response rate in TKI-naïve patients, demonstrating its effectiveness in patients with brain metastases and further solidifying its clinical value as a ROS1 inhibitor.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUVB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUVB
Wall Street analysts forecast NUVB stock price to rise
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.120
Low
8.00
Averages
11.38
High
18.00
Current: 5.120
Low
8.00
Averages
11.38
High
18.00
About NUVB
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IBTROZI Shows Outstanding Efficacy in Lung Cancer Treatment
- Impressive Efficacy Data: In TKI-naïve patients, IBTROZI achieved a confirmed objective response rate of 89.8%, with a median duration of response of 49.7 months and a median progression-free survival of 46.1 months, indicating significant efficacy in treating ROS1-positive non-small cell lung cancer and potentially redefining treatment standards.
- High CNS Response Rates: IBTROZI demonstrated an intracranial response rate of 76.5% in TKI-naïve patients with brain metastases, and 65.6% in TKI-pretreated patients, highlighting its potential in managing brain metastases and improving survival outcomes for patients.
- Favorable Safety Profile: The safety analysis of IBTROZI revealed a low treatment-emergent adverse event rate, with only 8.5% of patients discontinuing treatment due to adverse events, and no new safety signals identified, suggesting the drug's long-term use is viable.
- Preclinical Data Support: New preclinical data presented at AACR indicated that taletrectinib inhibits TRKB-mediated lung cancer cell migration, further supporting its application potential in lung cancer treatment and possibly providing new directions for future therapeutic strategies.
See More
Nuvation Bio Reports Long-Term Efficacy Data for IBTROZI®
- Efficacy Highlights: At AACR 2026, IBTROZI® (taletrectinib) demonstrated an 89.8% objective response rate in TKI-naïve patients, with a median duration of response of 49.7 months, indicating significant efficacy in treating ROS1-positive non-small cell lung cancer.
- Survival Extension: The long-term data analysis revealed a median progression-free survival of 46.1 months for TKI-naïve patients, reflecting IBTROZI's potential to extend patient survival and possibly redefine treatment standards for this disease.
- Favorable Safety Profile: Safety analysis of IBTROZI showed a low treatment discontinuation rate of only 8.5% due to adverse events, with no new safety signals identified, indicating its feasibility for long-term use.
- CNS Activity: IBTROZI exhibited a 76.5% intracranial response rate in TKI-naïve patients, demonstrating its effectiveness in patients with brain metastases and further solidifying its clinical value as a ROS1 inhibitor.
See More
Nuvation Bio to Host Q1 2026 Financial Results Conference Call
- Conference Call Announcement: Nuvation Bio will host a conference call on May 4, 2026, at 4:30 p.m. ET to discuss its Q1 2026 financial results and business updates, aiming to provide transparent communication to investors and the public.
- Participation Details: Investors and the public can register for the live webcast on Nuvation Bio's Investor Relations page, and dial +1 833-461-5787 (U.S. toll-free) with access code 266802059 to join the call, ensuring broad participation.
- Archived Recording: An archived recording will be available on Nuvation Bio's website for 90 days post-event, allowing those unable to attend live to review the meeting content, thereby enhancing information accessibility.
- Company Background: Founded in 2018, Nuvation Bio focuses on innovative drug development for cancer treatment, with a diverse pipeline including next-generation ROS1 inhibitor taletrectinib and brain-penetrant IDH1 inhibitor safusidenib, showcasing its strong capabilities in the biopharma sector.
See More
Nuvation Bio CRO Sells 200,000 Shares Amid Strategic Options Exercise
- Insider Selling Details: Kerry Wentworth, the Chief Regulatory Officer of Nuvation Bio, sold 200,000 shares of Class A Common Stock on April 6, 2026, for approximately $904,000, reducing his direct holdings by 79.05% from 253,000 to 53,000 shares, which may raise concerns about insider confidence in the company's future prospects.
- Transaction Context: This sale followed the exercise of options, and Wentworth retains 53,000 shares along with 700,000 stock options, indicating he still holds a material economic interest in Nuvation Bio, despite the significant reduction in direct stock ownership.
- Market Reaction and Investor Sentiment: Large insider sales often alert investors; however, such transactions are common in the biotech sector, particularly when executives lock in profits through options, suggesting that market sentiment may not be significantly impacted by this sale.
- Company Financial Overview: Despite a net loss of approximately $204.6 million over the past year, Nuvation Bio's revenue from its oncology drug Ibtrozi and its diversified R&D pipeline provide potential growth opportunities for long-term investors, particularly those with a higher risk tolerance.
See More
Nuvation Bio Executive Sells 200,000 Shares
- Share Sale Details: Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio, sold 200,000 shares of Class A Common Stock on April 6, 2026, for approximately $904,000 at $4.52 per share, reducing direct ownership from 253,000 to 53,000 shares, indicating a significant divestment by an executive.
- Options Exercise and Market Reaction: The transaction involved the exercise of options with an immediate sale and no indirect entities, and while insider selling may raise market concerns, it is a planned event, suggesting that market sentiment may remain unaffected.
- Company Financials: Nuvation Bio reported a net loss of approximately $204.6 million over the past year, which is typical for biotech firms heavily investing in R&D, and the future success of the company hinges on its pipeline performance, making it suitable for long-term investors with a high-risk tolerance.
- Market Competition and Investment Advice: Nuvation Bio focuses on innovative oncology therapeutics, and although it was not included in The Motley Fool Stock Advisor's top investment picks, its competitive edge and R&D potential in the biotechnology sector warrant attention.
See More
Nuvation Bio Expands Market Rights, Bullish Outlook
- Analyst Optimism: As of April 8, 2026, over 90% of analysts maintain a 'Buy' rating for Nuvation Bio Inc. (NYSE:NUVB), with a consensus price target of $12 indicating a potential upside of 166.08%, reflecting strong market confidence in its future performance.
- Strategic Expansion: On April 1, 2026, Nuvation Bio Inc. secured exclusive rights to develop and market safusidenib in Japan through a deal with Daiichi Sankyo, significantly enhancing the company's competitive position in the oncology market.
- Clinical Research Support: This expansion will facilitate the ongoing Phase 3 SIGMA study in Japan, providing access to all current and future data, which is crucial for improving treatment capabilities for IDH1-mutant glioma and has significant clinical implications.
- Drug Potential: As a maintenance treatment for high-risk astrocytoma, safusidenib has demonstrated promising efficacy in Phase 1 and 2 trials, including long-lasting responses and extended progression-free survival, further solidifying Nuvation Bio's position in the biopharmaceutical sector.
See More
IBTROZI Shows Outstanding Efficacy in Lung Cancer Treatment
- Impressive Efficacy Data: In TKI-naïve patients, IBTROZI achieved a confirmed objective response rate of 89.8%, with a median duration of response of 49.7 months and a median progression-free survival of 46.1 months, indicating significant efficacy in treating ROS1-positive non-small cell lung cancer and potentially redefining treatment standards.
- High CNS Response Rates: IBTROZI demonstrated an intracranial response rate of 76.5% in TKI-naïve patients with brain metastases, and 65.6% in TKI-pretreated patients, highlighting its potential in managing brain metastases and improving survival outcomes for patients.
- Favorable Safety Profile: The safety analysis of IBTROZI revealed a low treatment-emergent adverse event rate, with only 8.5% of patients discontinuing treatment due to adverse events, and no new safety signals identified, suggesting the drug's long-term use is viable.
- Preclinical Data Support: New preclinical data presented at AACR indicated that taletrectinib inhibits TRKB-mediated lung cancer cell migration, further supporting its application potential in lung cancer treatment and possibly providing new directions for future therapeutic strategies.
See More
Nuvation Bio Reports Long-Term Efficacy Data for IBTROZI®
- Efficacy Highlights: At AACR 2026, IBTROZI® (taletrectinib) demonstrated an 89.8% objective response rate in TKI-naïve patients, with a median duration of response of 49.7 months, indicating significant efficacy in treating ROS1-positive non-small cell lung cancer.
- Survival Extension: The long-term data analysis revealed a median progression-free survival of 46.1 months for TKI-naïve patients, reflecting IBTROZI's potential to extend patient survival and possibly redefine treatment standards for this disease.
- Favorable Safety Profile: Safety analysis of IBTROZI showed a low treatment discontinuation rate of only 8.5% due to adverse events, with no new safety signals identified, indicating its feasibility for long-term use.
- CNS Activity: IBTROZI exhibited a 76.5% intracranial response rate in TKI-naïve patients, demonstrating its effectiveness in patients with brain metastases and further solidifying its clinical value as a ROS1 inhibitor.
See More
Nuvation Bio to Host Q1 2026 Financial Results Conference Call
- Conference Call Announcement: Nuvation Bio will host a conference call on May 4, 2026, at 4:30 p.m. ET to discuss its Q1 2026 financial results and business updates, aiming to provide transparent communication to investors and the public.
- Participation Details: Investors and the public can register for the live webcast on Nuvation Bio's Investor Relations page, and dial +1 833-461-5787 (U.S. toll-free) with access code 266802059 to join the call, ensuring broad participation.
- Archived Recording: An archived recording will be available on Nuvation Bio's website for 90 days post-event, allowing those unable to attend live to review the meeting content, thereby enhancing information accessibility.
- Company Background: Founded in 2018, Nuvation Bio focuses on innovative drug development for cancer treatment, with a diverse pipeline including next-generation ROS1 inhibitor taletrectinib and brain-penetrant IDH1 inhibitor safusidenib, showcasing its strong capabilities in the biopharma sector.
See More
Nuvation Bio CRO Sells 200,000 Shares Amid Strategic Options Exercise
- Insider Selling Details: Kerry Wentworth, the Chief Regulatory Officer of Nuvation Bio, sold 200,000 shares of Class A Common Stock on April 6, 2026, for approximately $904,000, reducing his direct holdings by 79.05% from 253,000 to 53,000 shares, which may raise concerns about insider confidence in the company's future prospects.
- Transaction Context: This sale followed the exercise of options, and Wentworth retains 53,000 shares along with 700,000 stock options, indicating he still holds a material economic interest in Nuvation Bio, despite the significant reduction in direct stock ownership.
- Market Reaction and Investor Sentiment: Large insider sales often alert investors; however, such transactions are common in the biotech sector, particularly when executives lock in profits through options, suggesting that market sentiment may not be significantly impacted by this sale.
- Company Financial Overview: Despite a net loss of approximately $204.6 million over the past year, Nuvation Bio's revenue from its oncology drug Ibtrozi and its diversified R&D pipeline provide potential growth opportunities for long-term investors, particularly those with a higher risk tolerance.
See More
Nuvation Bio Executive Sells 200,000 Shares
- Share Sale Details: Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio, sold 200,000 shares of Class A Common Stock on April 6, 2026, for approximately $904,000 at $4.52 per share, reducing direct ownership from 253,000 to 53,000 shares, indicating a significant divestment by an executive.
- Options Exercise and Market Reaction: The transaction involved the exercise of options with an immediate sale and no indirect entities, and while insider selling may raise market concerns, it is a planned event, suggesting that market sentiment may remain unaffected.
- Company Financials: Nuvation Bio reported a net loss of approximately $204.6 million over the past year, which is typical for biotech firms heavily investing in R&D, and the future success of the company hinges on its pipeline performance, making it suitable for long-term investors with a high-risk tolerance.
- Market Competition and Investment Advice: Nuvation Bio focuses on innovative oncology therapeutics, and although it was not included in The Motley Fool Stock Advisor's top investment picks, its competitive edge and R&D potential in the biotechnology sector warrant attention.
See More
Nuvation Bio Expands Market Rights, Bullish Outlook
- Analyst Optimism: As of April 8, 2026, over 90% of analysts maintain a 'Buy' rating for Nuvation Bio Inc. (NYSE:NUVB), with a consensus price target of $12 indicating a potential upside of 166.08%, reflecting strong market confidence in its future performance.
- Strategic Expansion: On April 1, 2026, Nuvation Bio Inc. secured exclusive rights to develop and market safusidenib in Japan through a deal with Daiichi Sankyo, significantly enhancing the company's competitive position in the oncology market.
- Clinical Research Support: This expansion will facilitate the ongoing Phase 3 SIGMA study in Japan, providing access to all current and future data, which is crucial for improving treatment capabilities for IDH1-mutant glioma and has significant clinical implications.
- Drug Potential: As a maintenance treatment for high-risk astrocytoma, safusidenib has demonstrated promising efficacy in Phase 1 and 2 trials, including long-lasting responses and extended progression-free survival, further solidifying Nuvation Bio's position in the biopharmaceutical sector.
See More
